---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-24-000041"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:00:29.063045+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M

## Summary
- Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.
- Revenue $17.0M, down from $45.5M; primarily non-cash royalty and licensing; no J&J milestone.
- Cash $585M as of June 30, down from $697M at Dec 31; FY2024 cash guidance $475-525M.
- Regained exclusive worldwide rights to plamotamab (CD20 x CD3), a Phase 2-ready bispecific T-cell engager.
- Vudalimab (PD-1 x CTLA-4) data update and advancement decision for mCRPC expected H1 2025.

## SEC filing metadata
- accession: 0001326732-24-000041
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000041/0001326732-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673224000041/xncr-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-24-000041
- JSON: https://secwatch.observer/filing/0001326732-24-000041.json
- Plain text: https://secwatch.observer/filing/0001326732-24-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.